Skip to main
EKSO
EKSO logo

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc. anticipates a rebound in enterprise sales from integrated delivery networks (IDN) this year, which aligns with the expected improvement in the macroeconomic environment. The company is making significant advancements in its claims pipeline, which bodes well for the potential of its Indego Personal product as a substantial revenue driver in 2025 and beyond. Additionally, strategic partnerships aimed at enhancing the growth of Indego Personal further support a positive financial outlook for the company.

Bears say

Ekso Bionics Holdings Inc. reported total revenue of $3.4 million in the first quarter of 2025, reflecting a 10% year-over-year decline from $3.8 million in the same period in 2024 and falling short of consensus expectations of $4.6 million. The company has revised its revenue outlook for the EksoHealth channel downward for 2025 and beyond, anticipating adverse effects from ongoing economic uncertainty. Additionally, the presence of softer enterprise revenue attributed to customer budget cuts raises further concerns about the company's growth potential in key markets.

EKSO has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 2 analysts, EKSO has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.